Braidwell’s Climb Bio CLYM Stock Holding History

Braidwell’s Portfolio CLYM Stock Details CLYM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$36.5M	Buy	2,797,375 +1,267,700	+83%	+$13.1M	1.35%	27
2026 Q1	$10.5M	Buy	+1,529,675	New	+$8.82M	0.35%	72

Other funds holding CLYM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Braidwell's CLYM Position: Q2 2026 in Review

Braidwell increased its Climb Bio (CLYM) stake by 83% in Q2 2026, buying an estimated $13.1M and bringing the position to 2,797,375 shares worth $36.5M. The position accounts for 1.35% of the portfolio, ranked #27.

Braidwell first reported a position in CLYM in Q1 2026 and has held it in 2 quarters since. 109 funds tracked by Wall St. Rank hold CLYM as of Q2 2026.

Braidwell held 2,797,375 shares of Climb Bio worth $36.5M as of Q2 2026.
Braidwell bought 1,267,700 Climb Bio shares in Q2 2026, an estimated $13.1M.
Climb Bio made up 1.35% of Braidwell's portfolio in Q2 2026, its #27 holding.
Braidwell first reported a position in Climb Bio in Q1 2026 and has held it in 2 quarters since.
109 funds tracked by Wall St. Rank held Climb Bio as of Q2 2026.

Based on Braidwell's 13F filing for Q2 2026, filed 14 Aug 2026.